Hackelsberger, A <br/><br/>
A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.  [electronic resource] 

 -  Drug safety  Jul 1996 
 - 30-52 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>0114-5916 
<br/><br/><label>Standard No.: </label>10.2165/00002018-199615010-00003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amoxicillin--administration & dosage<br/>Anti-Bacterial Agents--therapeutic use<br/>Bismuth--therapeutic use<br/>Clarithromycin--administration & dosage<br/>Drug Therapy, Combination<br/>Dyspepsia--microbiology<br/>Helicobacter Infections--drug therapy<br/>Helicobacter pylori--drug effects<br/>Histamine H2 Antagonists--therapeutic use<br/>Humans<br/>Nitroimidazoles--therapeutic use<br/>Omeprazole--administration & dosage<br/>Penicillins--therapeutic use<br/>Peptic Ulcer--microbiology<br/>Proton Pump Inhibitors<br/>Risk Assessment<br/>Tetracyclines--therapeutic use